MRGFUS EXABLATE 2100

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 01,07 report with the FDA on 2013-09-05 for MRGFUS EXABLATE 2100 manufactured by Insightec Ltd.

Event Text Entries

[3818576] Pt received a uterine fibroid treatment on (b)(6) 2013 by dr (b)(6) at (b)(6). Pt was diagnosed with skin redness and small blisters resemble skin burn of 1st or 2nd degree. Pt was released home with flammazine (burn treatment ointment). It was reported following blisters infection, pt was admitted in the special unit for skin burns at (b)(6) hospital. Pt underwent surgical resection of the burned tissue on the abdominal surface. Surgery went well without complications. Currently pt is recovering at home.
Patient Sequence No: 1, Text Type: D, B5


[11177463] Device has been diagnosed to work according to it's specifications. Reason of adverse event may be defined as user error. Treating physician failed to notice skin heating. Insightec training material already explains and address such situations thus we did not find any room for improvement of procedure. Incident discussed with the site. Summary: there was no device malfunction or deterioration that would have caused this event. Our detailed analysis of this particular case shows that starting from sonication #15, we see several sonications showing temperature rise on the gel pad - skin interface, and some showing skin hyperemia on the magnitude fat saturated images. Otherwise, there were no unusual findings in pt positioning, treatment planning or treatment parameters. Because of the skin burn location, i. E. : gel pad-skin interface, we can only assume that the acoustic coupling between the pt and the gel pad around the location of the skin was problematic. Based on insightec past experience with these type of events, this could have been induced by microscopic air bubbles, or hydrophobic skin (i. E. Skin was not properly cleaned from potential oil based by-products). In any event, the treating physician did not notice the effects that were displayed on the mr images following sonication#15 and up. Action following this real time feedback could have helped minimize the event. Skin burn events are well known risks for the focused ultrasound procedure. However, the steps to eliminate them are also well known. In fact, since the implementation of all the mitigating steps in our insightec training, these events are indeed fairly rare. In response to this particular case, insightec application team will reach out to the treating physician to re-emphasize the role of the real time mr intra-procedure imaging, as well as full review of the steps to mitigate this type of events. It should be noted that this particular treating physician has treated more than 300 pts at a rate of 1 to 2 pts a day, and this is the first time they encountered such an event.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number9615058-2013-00001
MDR Report Key3335967
Report Source01,07
Date Received2013-09-05
Date of Report2012-01-24
Date of Event2012-12-12
Date Mfgr Received2013-08-10
Device Manufacturer Date2010-05-01
Date Added to Maude2013-09-10
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer ContactORI LUBIN, MGR
Manufacturer Street5 NAHUM HETH ST PO BOX 2039
Manufacturer CityTIRAT CARMEL 31290
Manufacturer CountryIS
Manufacturer Postal31290
Manufacturer Phone544881399
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameMRGFUS EXABLATE
Generic NameFOCUSSED ULTRASOUND
Product CodeNRZ
Date Received2013-09-05
Model Number2100
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device AgeDA
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerINSIGHTEC LTD
Manufacturer Address5 NAHUM HET TIRAT CARMEL 3912001 IS 3912001


Patients

Patient NumberTreatmentOutcomeDate
101. Hospitalization; 2. Required No Informationntervention 2013-09-05

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.